Medical Equipment/Supplies/Accessories · Founded 2016 · www.nureca.com · BSE 543264 · NSE NURECA · ISIN INE0DSF01015
No Notes Added Yet
Business
Nureca Ltd. is an Indian company primarily engaged in the B2C distribution of home healthcare and wellness products. The company operates under its flagship brand "Dr Trust," offering a wide range of medical devices such accessories, oximeters, nebulizers, blood pressure monitors, thermometers, glucometers, weighing scales, and massagers. It also sells nutrition and lifestyle products, including smartwatches and fitness bands, under the "Dr Physio" and "Dr Nutrica" brands. Nureca's core business model revolves around selling these products directly to consumers, primarily through online e-commerce platforms like Amazon, Flipkart, and its own website, complemented by a growing presence in offline retail channels. The company makes money by sourcing products (often manufactured by third parties) and selling them at a markup to end-users.
Revenue Mix
Nureca's revenue is largely driven by its home healthcare medical devices segment under the "Dr Trust" brand, which includes products for monitoring vital signs, respiratory care, and pain management. While exact segment breakdowns are not always publicly detailed, this segment forms the bulk of its sales. The company has been expanding into nutrition and lifestyle products (e.g., smartwatches, protein supplements), which represent a smaller but growing portion of its revenue. Its sales are predominantly driven by its online presence across major e-commerce marketplaces and its direct-to-consumer website.
Industry
Nureca operates in the rapidly growing Indian home healthcare and wellness market. This industry is characterized by increasing health consciousness, rising incidence of lifestyle diseases, an aging population, and a shift towards preventive care and self-monitoring. The market is competitive, with both organized international players (e.g., Omron, Philips) and a multitude of domestic and unorganized brands. Nureca has carved out a strong niche in the online direct-to-consumer (D2C) space, leveraging its "Dr Trust" brand to gain significant market share in specific product categories like nebulizers and oximeters through aggressive online marketing and competitive pricing. Its positioning is as an accessible, trusted brand for home medical and wellness devices, especially appealing to the digitally savvy consumer base.
MOAT
Nureca's competitive advantages primarily stem from:
Brand Recognition: The "Dr Trust" brand has established significant visibility and trust among online consumers for home healthcare products.
Strong E-commerce Presence: Early and effective penetration of major online marketplaces provides a wide distribution reach and reduces reliance on traditional retail infrastructure.
Wide Product Portfolio: A comprehensive range of affordable products caters to diverse consumer needs in the home healthcare segment, fostering cross-selling opportunities.
Agility & Responsiveness: Ability to quickly identify market demand and introduce new products, especially evident during the pandemic for products like oximeters and nebulizers.
Cost Efficiency: A lean operating model focused on online distribution helps maintain competitive pricing.
Growth Drivers
Key factors that can drive Nureca's growth over the next 3-5 years include:
Increasing Health Awareness & Preventive Care: Growing consumer focus on health monitoring and early detection drives demand for home medical devices.
Digital Adoption & E-commerce Penetration: Continued growth of online shopping in India directly benefits Nureca's primary sales channel.
Expansion of Product Portfolio: Introduction of new and innovative home healthcare, nutrition, and wellness products.
Offline Channel Expansion: Strategic expansion into offline retail stores and pharmacies to tap into broader customer segments.
Rising Incidence of Lifestyle Diseases: Conditions like diabetes, hypertension, and respiratory issues necessitate continuous home monitoring.
Aging Population: An increasing elderly demographic requires more home-based medical support.
Risks
Intense Competition: The market is highly fragmented, with competition from established global brands and aggressive domestic players leading to potential price wars and margin pressure.
Supply Chain Vulnerabilities: Reliance on imported components and third-party manufacturing exposes the company to global supply chain disruptions, currency fluctuations, and geopolitical risks.
Regulatory Changes: Evolving regulations for medical devices and e-commerce could impact operations and compliance costs.
Product Quality & Recalls: Any issues with product quality or safety could severely damage brand reputation and lead to costly recalls.
E-commerce Platform Dependence: Significant reliance on major online marketplaces means exposure to their changing policies, algorithms, and commission structures.
Technological Obsolescence: Rapid advancements in medical technology could render existing products outdated quickly, requiring continuous R&D and product refresh.
Economic Downturn: Discretionary spending on wellness and non-essential medical devices could be impacted during economic slowdowns.
Management & Ownership
Nureca Ltd. was founded by Mr. Saurabh Goyal, who serves as the Managing Director and CEO. He is the key promoter and has been instrumental in shaping the company's digital-first strategy and brand building. The management team focuses on leveraging technology and e-commerce for market penetration. Promoter ownership typically constitutes a significant portion, demonstrating strong alignment with the company's long-term vision. The company operates with a relatively lean structure, emphasizing agility and direct consumer engagement.
Outlook
Nureca is well-positioned to capitalize on the secular growth trends in India's home healthcare and wellness market, driven by increasing health awareness and digital adoption. Its strong "Dr Trust" brand and established e-commerce presence provide a foundation for continued revenue growth and market expansion. The company's ability to innovate and expand its product portfolio into new segments like smart wearables and nutrition offers additional avenues for growth. However, the outlook is balanced by significant competitive pressures, potential supply chain disruptions, and the need for continuous product innovation and quality control. Maintaining brand loyalty and effective cost management will be crucial for sustaining profitability amidst intense market rivalry. The company's future success will depend on its execution capabilities in product diversification, strengthening its offline presence, and navigating the evolving regulatory landscape while fending off competition.
| #(Fig in Cr.) | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 17 | 20 | 31 | 26 | 32 | 34 | 38 | 40 | 35 | 40 |
| Other Income | -1 | 6 | 3 | 1 | 2 | 3 | 2 | 2 | 1 | 2 |
| Total Income | 16 | 26 | 34 | 28 | 34 | 37 | 40 | 42 | 36 | 42 |
| Total Expenditure | 21 | 23 | 34 | 30 | 31 | 35 | 34 | 36 | 41 | 37 |
| Operating Profit | -6 | 3 | 1 | -3 | 3 | 2 | 6 | 5 | -5 | 5 |
| Interest | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | -6 | 3 | -0 | -3 | 2 | 1 | 5 | 5 | -6 | 4 |
| Provision for Tax | -2 | 1 | 0 | -0 | -0 | 0 | 1 | 1 | 1 | 1 |
| Profit After Tax | -4 | 2 | -0 | -3 | 2 | 1 | 4 | 4 | -6 | 3 |
| Adjustments | 0 | 0 | 0 | 0 | -0 | 0 | 0 | 0 | 0 | -0 |
| Profit After Adjustments | -4 | 2 | -0 | -3 | 2 | 1 | 4 | 4 | -6 | 3 |
| Adjusted Earnings Per Share | -4.1 | 1.7 | -0.5 | -2.8 | 2.5 | 0.8 | 3.6 | 3.7 | -6.4 | 3.2 |
| #(Fig in Cr.) | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 20 | 62 | 99 | 213 | 256 | 111 | 92 | 110 | 147 | 153 |
| Other Income | 0 | 0 | 0 | 3 | 8 | 7 | 11 | 13 | 8 | 7 |
| Total Income | 20 | 62 | 99 | 216 | 263 | 118 | 102 | 122 | 155 | 160 |
| Total Expenditure | 16 | 53 | 90 | 152 | 200 | 126 | 102 | 117 | 147 | 148 |
| Operating Profit | 4 | 9 | 10 | 64 | 63 | -8 | 0 | 5 | 8 | 11 |
| Interest | 0 | 0 | 1 | 2 | 1 | 0 | 0 | 1 | 1 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 2 | 2 | 3 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 4 | 9 | 9 | 62 | 61 | -11 | -3 | 1 | 5 | 8 |
| Provision for Tax | 1 | 3 | 2 | 16 | 16 | -2 | -1 | 0 | 3 | 4 |
| Profit After Tax | 3 | 6 | 6 | 46 | 45 | -8 | -2 | 1 | 2 | 5 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 3 | 6 | 6 | 46 | 45 | -8 | -2 | 1 | 2 | 5 |
| Adjusted Earnings Per Share | 444.6 | 889.4 | 913.6 | 46.4 | 45 | -8.3 | -1.8 | 0.8 | 2.2 | 4.1 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 34% | 10% | -7% | 0% |
| Operating Profit CAGR | 60% | 0% | -34% | 0% |
| PAT CAGR | 100% | 0% | -47% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -7% | -5% | -30% | NA% |
| ROE Average | 1% | 0% | 4% | 80% |
| ROCE Average | 3% | 1% | 6% | 66% |
| #(Fig in Cr.) | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 2 | 8 | 15 | 163 | 203 | 195 | 193 | 194 | 181 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 0 | 0 | 9 | 1 | 0 | 0 | 0 | 1 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 2 | 4 | 0 | -2 | -1 | -1 |
| Total Current Liabilities | 5 | 15 | 10 | 24 | 45 | 9 | 9 | 12 | 14 |
| Total Liabilities | 7 | 24 | 34 | 190 | 252 | 204 | 200 | 207 | 194 |
| Fixed Assets | 0 | 1 | 1 | 4 | 10 | 9 | 7 | 9 | 14 |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 3 | 9 | 1 | 8 | 65 |
| Total Current Assets | 7 | 23 | 33 | 186 | 239 | 187 | 193 | 190 | 115 |
| Total Assets | 7 | 24 | 34 | 190 | 252 | 204 | 200 | 207 | 194 |
| #(Fig in Cr.) | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 0 | 0 | 0 | 0 | 17 | 8 | 1 | 14 | 3 |
| Cash Flow from Operating Activities | 0 | 0 | -8 | 35 | 1 | 10 | -3 | -19 | 3 |
| Cash Flow from Investing Activities | -0 | -0 | -0 | -110 | -3 | -16 | 18 | 8 | 14 |
| Cash Flow from Financing Activities | -0 | -0 | 8 | 92 | -7 | -2 | -1 | -0 | -20 |
| Net Cash Inflow / Outflow | 0 | 0 | -0 | 17 | -9 | -8 | 14 | -11 | -2 |
| Closing Cash & Cash Equivalent | 0 | 0 | 0 | 17 | 8 | 1 | 14 | 3 | 1 |
| # | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 444.57 | 889.43 | 913.57 | 46.37 | 44.96 | -8.25 | -1.79 | 0.85 | 2.18 |
| CEPS(Rs) | 445.43 | 897.57 | 967 | 46.8 | 46.44 | -5.86 | 0.57 | 3.18 | 4.29 |
| DPS(Rs) | 0 | 0 | 0 | 2 | 3 | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 104.29 | 993.57 | 1990.71 | 163.1 | 203.2 | 194.88 | 193.11 | 194.29 | 189.44 |
| Core EBITDA Margin(%) | 21.82 | 14.2 | 9.37 | 27.36 | 20.55 | -12.87 | -10.23 | -6.4 | 0.11 |
| EBIT Margin(%) | 21.88 | 14.25 | 9.07 | 28.42 | 22.85 | -8.83 | -2.06 | 2.1 | 3.93 |
| Pre Tax Margin(%) | 21.56 | 13.87 | 8.32 | 27.71 | 22.57 | -9.21 | -2.54 | 1.1 | 3.13 |
| PAT Margin (%) | 15.52 | 9.77 | 6.18 | 20.62 | 16.64 | -7.08 | -1.79 | 0.69 | 1.31 |
| Cash Profit Margin (%) | 15.55 | 9.86 | 6.55 | 20.8 | 17.19 | -5.03 | 0.57 | 2.61 | 2.57 |
| ROA(%) | 44.35 | 40.78 | 22.3 | 41.38 | 20.33 | -3.62 | -0.89 | 0.42 | 1.04 |
| ROE(%) | 426.3 | 162.03 | 61.23 | 52.39 | 24.55 | -4.14 | -0.92 | 0.44 | 1.11 |
| ROCE(%) | 255.06 | 179.97 | 56.7 | 67.61 | 33.57 | -5.17 | -1.06 | 1.31 | 3.31 |
| Receivable days | 30.69 | 30.18 | 38.39 | 10.65 | 2.11 | 11.25 | 10.79 | 7.39 | 12.7 |
| Inventory Days | 64.42 | 48.92 | 52.9 | 43.16 | 67.53 | 152.88 | 119.26 | 105.87 | 100.27 |
| Payable days | 172.97 | 68.29 | 44.04 | 26.74 | 18.53 | 23.46 | 30.6 | 31.48 | 22.92 |
| PER(x) | 0 | 0 | 0 | 12.98 | 30.3 | 0 | 0 | 248.64 | 94.46 |
| Price/Book(x) | 0 | 0 | 0 | 3.69 | 6.7 | 1.54 | 1.32 | 1.08 | 1.09 |
| Dividend Yield(%) | 0 | 0 | 0 | 0.33 | 0.22 | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | -0 | 0.01 | 0.1 | 2.23 | 5 | 2.06 | 2.29 | 0.78 | 1.06 |
| EV/Core EBITDA(x) | -0.01 | 0.04 | 1 | 7.41 | 20.22 | -29.03 | 685.11 | 17.43 | 18.84 |
| Net Sales Growth(%) | 0 | 208.7 | 60.63 | 114.69 | 19.72 | -56.44 | -17.42 | 19.29 | 34.02 |
| EBIT Growth(%) | 0 | 107.07 | 3.27 | 581.55 | -3.46 | -116.67 | 80.03 | 224.43 | 144.86 |
| PAT Growth(%) | 0 | 100.06 | 2.71 | 625.16 | -3.05 | -118.35 | 78.25 | 147.16 | 145.86 |
| EPS Growth(%) | 0 | 100.06 | 2.71 | -94.92 | -3.05 | -118.35 | 78.25 | 147.16 | 157.91 |
| Debt/Equity(x) | 0 | 0.06 | 0.7 | 0.01 | 0 | 0 | 0 | 0.01 | 0 |
| Current Ratio(x) | 1.32 | 1.5 | 3.45 | 7.78 | 5.28 | 21 | 20.77 | 15.32 | 8.32 |
| Quick Ratio(x) | 0.65 | 0.62 | 1.72 | 6.24 | 3.89 | 17.12 | 17.44 | 12.1 | 4.88 |
| Interest Cover(x) | 68.55 | 37.38 | 12.14 | 39.89 | 83.3 | -22.87 | -4.2 | 2.11 | 4.88 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.01 | 0 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 63.24 | 63.24 | 63.77 | 64.06 | 64.3 | 64.33 | 64.97 | 68.09 | 68.09 | 68.09 |
| FII | 0.07 | 0.07 | 0.69 | 0.36 | 1.07 | 0.07 | 0.07 | 0.08 | 0.28 | 0.11 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.2 | 0.2 |
| Public | 36.69 | 36.69 | 35.53 | 35.58 | 34.62 | 35.6 | 34.95 | 31.82 | 31.43 | 31.6 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0.63 | 0.63 | 0.64 | 0.64 | 0.64 | 0.64 | 0.65 | 0.65 | 0.65 | 0.65 |
| FII | 0 | 0 | 0.01 | 0 | 0.01 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 0.37 | 0.37 | 0.36 | 0.36 | 0.35 | 0.36 | 0.35 | 0.3 | 0.3 | 0.3 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.95 | 0.95 | 0.95 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | +34% | +10% | -7% | — |
| Operating Profit CAGR | +60% | — | -34% | — |
| PAT CAGR | +100% | — | -47% | — |
| Share Price CAGR | -7% | -5% | -30% | — |
| ROE Average | +1% | 0% | +4% | +80% |
| ROCE Average | +3% | +1% | +6% | +66% |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 63.24 | 63.24 | 63.77 | 64.06 | 64.3 | 64.33 | 64.97 | 68.09 | 68.09 | 68.09 |
| FII | 0.07 | 0.07 | 0.69 | 0.36 | 1.07 | 0.07 | 0.07 | 0.08 | 0.28 | 0.11 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.2 | 0.2 |
| Public | 36.69 | 36.69 | 35.53 | 35.58 | 34.62 | 35.6 | 34.95 | 31.82 | 31.43 | 31.6 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0.63 | 0.63 | 0.64 | 0.64 | 0.64 | 0.64 | 0.65 | 0.65 | 0.65 | 0.65 |
| FII | 0 | 0 | 0.01 | 0 | 0.01 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 0.37 | 0.37 | 0.36 | 0.36 | 0.35 | 0.36 | 0.35 | 0.3 | 0.3 | 0.3 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.95 | 0.95 | 0.95 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
Your relationship manager will connect with you shortly.